Abemaciclib for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence

As of July 2022, MARA’s assessment finds Abemaciclib’s reimbursement risk concentrated in safety and adverse effects, with comparator selection a strength; the current MARA Rating and full rationale are available in the report.

The assessment also weighs care pathway integration: how the drug fits into the way care is organised today; a treatment that demands new infrastructure or displaces an established pathway faces extra scrutiny. The strength recorded in comparator selection carries weight because that domain asks whether the drug was tested against the treatment payers actually fund today; a benefit shown against the wrong comparator carries little weight in a reimbursement decision.

Oncology

This rating sits within MARA’s Oncology coverage, alongside 153 other independently assessed treatments in the same area.

What payers will ask

Is the clinical benefit the kind payers reward? — Clinical effectiveness

The evidence from the monarchE trial indicates that abemaciclib with endocrine therapy significantly improves invasive disease-free survival compared to endocrine therapy alone, with a hazard ratio of 0.680. This suggests a clear clinical advantage, although the long-term benefits remain uncertain due to ongoing data collection.

Does the economic case hold at the expected price? — Cost effectiveness

The most plausible ICER for abemaciclib with endocrine therapy is estimated at £9,164 per QALY gained, which is within the range considered acceptable by NICE, indicating marginal cost-effectiveness.

Is there quality-of-life evidence payers weigh? — Quality of life

The document indicates that the treatment addresses significant unmet needs and improves quality of life by reducing the risk of cancer recurrence, although specific HRQoL data from validated instruments is not detailed.

Does the safety profile hold up for payers? — Safety and Adverse Effects

The safety profile of abemaciclib is considered acceptable, with manageable adverse effects such as diarrhea. The committee concluded that the benefits outweigh the risks, although treatment discontinuations due to adverse events were noted.

Was the drug compared against what payers expect? — Comparator Selection

The treatment was compared against the standard of care (endocrine therapy alone) in a well-defined patient population, which is appropriate for assessing its effectiveness.

Is the population defined the way payers need it? — Patient Population and Subgroups

The trial population is representative of the intended patient population, with specific inclusion criteria that reflect those at high risk of recurrence, enhancing generalizability to Healthcare practice.

Does the drug fit how care is delivered and paid for? — Care Pathway Integration

The integration of abemaciclib into existing treatment pathways is feasible with minor adjustments, as it complements current adjuvant therapies without requiring extensive new infrastructure.

Are the wider system costs understood? — Resource Use and Cost Implications

The economic model suggests that while there is a notable cost burden, it is justifiable given the potential benefits and the confidential discount arrangements in place.

Would the evidence survive payer scrutiny? — Evidence Quality and Robustness

The evidence is derived from a large, ongoing Phase III trial (monarchE) with a robust design, although some uncertainties regarding long-term outcomes remain.

How exposed is the case to uncertainty? — Uncertainty, Sensitivity, and Broader Impacts

While there are uncertainties regarding treatment effect duration and cost-effectiveness estimates, the context of high unmet need and the potential for significant patient benefit mitigate these concerns.

Request the current rating

Be alerted when this rating changes:

Related Reimbursement Risk Assessments

Public record

The entries below are official decisions and assessments concerning this drug and indication, listed with their dates as a matter of record. The assessment on this page reflects the evidence available as of its date.

20 August 2026 — Germany (G-BA), benefit assessment (reassessment after expiry of the time-limited decision): minor additional benefit for premenopausal patients; no additional benefit proven for postmenopausal patients. official record

Full Legal Disclaimer and Usage Terms

The MARA Rating® is an independent opinion of a drug’s market access pharma risk profile and is provided for informational purposes only—not as investment, medical, legal or any other type of advice. See our full disclaimer here.